白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2011年
8期
486-489
,共4页
翟欣辉%魏绪仓%王一%赵园%连小赟%张玎%苗玉迪
翟訢輝%魏緒倉%王一%趙園%連小赟%張玎%苗玉迪
적흔휘%위서창%왕일%조완%련소빈%장정%묘옥적
白血病%沙利度胺%血管内皮生长因子类%受体,血管内皮生长因子%成纤维细胞生长因子2
白血病%沙利度胺%血管內皮生長因子類%受體,血管內皮生長因子%成纖維細胞生長因子2
백혈병%사리도알%혈관내피생장인자류%수체,혈관내피생장인자%성섬유세포생장인자2
Leukemia%Thalidomide%Vascular endothelial growth factors%Receptors,vascular endothelial growth factor%,Fibroblast growth factor 2
目的 观察沙利度胺联合化疗治疗急性白血病的临床疗效及其对血浆血管内皮生长因子(VEGF)、血管内皮生长因子受体(VEGFR)、碱性成纤维细胞生长因子(bFGF)水平的影响.方法 急性白血病患者36例,随机分为试验组及对照组各18例.每组均予以常规化疗方案标准剂量化疗,试验组同时口服沙利度胺100 mg/d.治疗前及治疗后8周分别采集外周血,双抗体夹心酶联免疫吸附法(ELISA)检测血浆VEGF、VEGFR、bFGF含量.以15位健康体检者为健康对照组.结果 试验组与对照组有效率分别为88.9%(16/18)和77.8%(14/18),差异有统计学意义(x2=4.103,P＜0.05).试验组与对照组治疗前血浆VEGF水平分别为(389.78±249.94)和(318.54±125.78)pg/ml,高于健康组的(132.91±26.66)pg/ml(t=3.141、3.024,均P＜0.01);治疗后分别为(211.74±36.72)和(288.02±31.77)pg/ml,高于健康组(t=2.413、2.324,均P＜0.05);试验组与对照组治疗前VEGF差异无统计学意义(t=1.384,P＞0.05),治疗后差异有统计学意义(t=2.793,P＜0.05).试验组与对照组治疗前血浆VEGFR水平分别为(2490.75±1695.9)和(2322.78±1105.87)pg/ml,高于健康组的(1134.98±378.45)pg/ml(t=2.914、2.783,均P＜0.01);治疗后分别为(1359.71±390.24)和(1753.89±337.04)pg/ml,与健康组相比差异有统计学意义(t=2.572、2.447,均P＜0.05);试验组与对照组治疗前VEGFR差异无统计学意义(t=1.276,P＞0.05),治疗后差异有统计学意义(t=2.486,P＜0.05).试验组与对照组治疗前血浆bFGF水平分别为(2.43±0.27)和(2.4l±0.33)ng/ml,高于健康组的(1.83±0.44)ng/ml(t=4.982、4.171,均P＜0.05);治疗后分别为(2.09±0.17)和(2.11±0.31)ng/ml,与健康组相比差异有统计学意义(t=3.01l、2.773,均P＜0.05);试验组与对照组治疗前及治疗后相比差异无统计学意义(t=0.953、1.282,均P＞0.05).结论 沙利度胺联合化疗可提高急性白血病患者的缓解率,有可能成为一种通过抗血管新生从而抑制白血病细胞生长及浸润的有效治疗方法.
目的 觀察沙利度胺聯閤化療治療急性白血病的臨床療效及其對血漿血管內皮生長因子(VEGF)、血管內皮生長因子受體(VEGFR)、堿性成纖維細胞生長因子(bFGF)水平的影響.方法 急性白血病患者36例,隨機分為試驗組及對照組各18例.每組均予以常規化療方案標準劑量化療,試驗組同時口服沙利度胺100 mg/d.治療前及治療後8週分彆採集外週血,雙抗體夾心酶聯免疫吸附法(ELISA)檢測血漿VEGF、VEGFR、bFGF含量.以15位健康體檢者為健康對照組.結果 試驗組與對照組有效率分彆為88.9%(16/18)和77.8%(14/18),差異有統計學意義(x2=4.103,P＜0.05).試驗組與對照組治療前血漿VEGF水平分彆為(389.78±249.94)和(318.54±125.78)pg/ml,高于健康組的(132.91±26.66)pg/ml(t=3.141、3.024,均P＜0.01);治療後分彆為(211.74±36.72)和(288.02±31.77)pg/ml,高于健康組(t=2.413、2.324,均P＜0.05);試驗組與對照組治療前VEGF差異無統計學意義(t=1.384,P＞0.05),治療後差異有統計學意義(t=2.793,P＜0.05).試驗組與對照組治療前血漿VEGFR水平分彆為(2490.75±1695.9)和(2322.78±1105.87)pg/ml,高于健康組的(1134.98±378.45)pg/ml(t=2.914、2.783,均P＜0.01);治療後分彆為(1359.71±390.24)和(1753.89±337.04)pg/ml,與健康組相比差異有統計學意義(t=2.572、2.447,均P＜0.05);試驗組與對照組治療前VEGFR差異無統計學意義(t=1.276,P＞0.05),治療後差異有統計學意義(t=2.486,P＜0.05).試驗組與對照組治療前血漿bFGF水平分彆為(2.43±0.27)和(2.4l±0.33)ng/ml,高于健康組的(1.83±0.44)ng/ml(t=4.982、4.171,均P＜0.05);治療後分彆為(2.09±0.17)和(2.11±0.31)ng/ml,與健康組相比差異有統計學意義(t=3.01l、2.773,均P＜0.05);試驗組與對照組治療前及治療後相比差異無統計學意義(t=0.953、1.282,均P＞0.05).結論 沙利度胺聯閤化療可提高急性白血病患者的緩解率,有可能成為一種通過抗血管新生從而抑製白血病細胞生長及浸潤的有效治療方法.
목적 관찰사리도알연합화료치료급성백혈병적림상료효급기대혈장혈관내피생장인자(VEGF)、혈관내피생장인자수체(VEGFR)、감성성섬유세포생장인자(bFGF)수평적영향.방법 급성백혈병환자36례,수궤분위시험조급대조조각18례.매조균여이상규화료방안표준제양화료,시험조동시구복사리도알100 mg/d.치료전급치료후8주분별채집외주혈,쌍항체협심매련면역흡부법(ELISA)검측혈장VEGF、VEGFR、bFGF함량.이15위건강체검자위건강대조조.결과 시험조여대조조유효솔분별위88.9%(16/18)화77.8%(14/18),차이유통계학의의(x2=4.103,P＜0.05).시험조여대조조치료전혈장VEGF수평분별위(389.78±249.94)화(318.54±125.78)pg/ml,고우건강조적(132.91±26.66)pg/ml(t=3.141、3.024,균P＜0.01);치료후분별위(211.74±36.72)화(288.02±31.77)pg/ml,고우건강조(t=2.413、2.324,균P＜0.05);시험조여대조조치료전VEGF차이무통계학의의(t=1.384,P＞0.05),치료후차이유통계학의의(t=2.793,P＜0.05).시험조여대조조치료전혈장VEGFR수평분별위(2490.75±1695.9)화(2322.78±1105.87)pg/ml,고우건강조적(1134.98±378.45)pg/ml(t=2.914、2.783,균P＜0.01);치료후분별위(1359.71±390.24)화(1753.89±337.04)pg/ml,여건강조상비차이유통계학의의(t=2.572、2.447,균P＜0.05);시험조여대조조치료전VEGFR차이무통계학의의(t=1.276,P＞0.05),치료후차이유통계학의의(t=2.486,P＜0.05).시험조여대조조치료전혈장bFGF수평분별위(2.43±0.27)화(2.4l±0.33)ng/ml,고우건강조적(1.83±0.44)ng/ml(t=4.982、4.171,균P＜0.05);치료후분별위(2.09±0.17)화(2.11±0.31)ng/ml,여건강조상비차이유통계학의의(t=3.01l、2.773,균P＜0.05);시험조여대조조치료전급치료후상비차이무통계학의의(t=0.953、1.282,균P＞0.05).결론 사리도알연합화료가제고급성백혈병환자적완해솔,유가능성위일충통과항혈관신생종이억제백혈병세포생장급침윤적유효치료방법.
Objective To observe on the clinical effect and the influence of the level of plasma vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR) and basic fibroblast growth factor (bFGF) in acute leukemia before and after treatment by thalidomide combined with chemotherapy. Methods Thirty-six cases of acute leukemia patients were randomly divided into experimental group and control group by 18 cases each. Each group was treated with conventional chemotherapy in the standard-dose, meanwhile in the experimental group additional thalidomide 100 mg/day were taken orally. Before treatment and 8 weeks after treatment, plasma were collected for the detection of VEGF, VEGFR and bFGF content by double antibody sandwich enzyme-linked immunosorbent assay (ELISA).Results The ratio of experimental group and control group, were 88.9 % (16/18), 77.8 % (14/18)respectively and the difference was statistically significant (x2 =4.103, P ＜0.05). The level of plasma VEGF (389.78+249.94 pg/ml, 318.54±125.78 pg/ml) of experimental group and control group before treatment was statistically significant (t = 3.141, t =3.024, P ＜0.01) compared with healthy group [(132.91±26.66) pg/ml] respectively. The level of plasma VEGF of those groups after treatment [(211.74+36.72) pg/ml, (288.02±31.77) pg/ml] was statistically significant (t =2.413, t =2.324, P ＜0.05) compared with healthy group respectively. The difference of the level of plasma VEGF of experimental group and control group before treatment was not statistically significant (t =1.384, P ＞0.05). The difference of the level of plasma VEGF of experimental group and control group after treatment was statistically significant(t =2.793,P ＜0.05). The level of plasma VEGFR [(2490.75+1695.9) pg/ml, (2322.78+1105.87) pg/ml] of experimental group and control group before treatment was statistically significant (t =2.914, t =2.783, P ＜0.01) compared with healthy group [(1134.98+378.45) pg/ml] respectively. The level of plasma VEGFR of those groups after treatment [(1359.71± 390.24) pg/ml, (1753.89±337.04) pg/ml] was statistically significant(t =2.572, t =2.447, P ＜0.05) compared with healthy group respectively. The difference of the level of plasma VEGFR of experimental group and control group before treatment was not statistically significant (t =1.276, P ＞0.05). The difference of the level of plasma VEGFR of experimental group and control group after treatment was statistically significant (t = 2.486, P ＜0.05). The level of plasma bFGF [(2.43±0.27) ng/ml, (2.41±0.33) ng/ml] of experimental group and control group before treatment was statistically significant(t =4.982, t =4.171, P ＜0.05) compared with healthy group (1.83±0.44) ng/ml respectively; the level of plasma bFGF of those groups after treatment [(2.09±0.17) ng/ml,(2.11±0.31) ng/ml] was statistically significant (t =3.011, t =2.773, P ＜0.05) compared with healthy group respectively. The difference of the level of plasma bFGF of experimental group and control group before treatment was not statistically significant (t =0.953, P ＞0.05). The difference of the level of plasma bFGF of experimental group and control group after treatment was not statistically significant (t =1.282, P ＞0.05).Conclusion The remission rate could be improved by thalidomide combined with chemotherapy in acute leukemia, which could be an effective treatment by anti-angiogenesis and inhibiting the growth and infiltration of acute leukemia cells.
